A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
Open Forum Infect Dis
.
2019 Jan 16;6(2):ofz035.
doi: 10.1093/ofid/ofz035.
eCollection 2019 Feb.
Authors
Julian P Kaboggoza
1
,
Xinxhu Wang
2
,
Megan Neary
3
,
Pedro Ayuso
3
,
Christine Sekaggya-Wiltshire
1
,
Shadia Nakalema
1
,
Andrew Owen
3
,
Myra McClure
2
,
Mohammed Lamorde
1
,
Marta Boffito
2
4
Affiliations
1
Infectious Diseases Institute, Makerere University College of Health Sciences, Mulago Hospital Complex, Kampala, Uganda.
2
Jeffriess Research Trust Laboratories, Department of Medicine, Imperial College, London, United Kingdom.
3
Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, United Kingdom.
4
St Stephen's Clinical Research, Chelsea and Westminster Hospital, London, United Kingdom.
PMID:
30815503
PMCID:
PMC6386798
DOI:
10.1093/ofid/ofz035
No abstract available
Keywords:
HIV; isoniazid/rifampicin; low-dose efavirenz; pharmacokinetics; tuberculosis.